TEL AVIV, Israel, June 18, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage orphan disease-focused biotechnology company, announced today that it will present pre-clinical proofs of concept for two of its therapeutic platforms during June.
At the 19th International SMA Researcher Meeting in Kansas City, MO (see details below), BioBlast will present its proof of concept for BBrm02 (intrathecally-administered azithromycin) for Spinal Muscular Atrophy, its lead drug candidate in its Read-through Platform.
At the United Mitochondrial Disease Foundation – Mitochondrial Medicine 2015 Meeting, in Herndon, VA (see details below), BioBlast will present its proof of concept for BB-FA (frataxin protein replacement) for Friedreich's Ataxia, its lead drug candidate in its Mitochondrial Protein Replacement Platform (mPRT).
|Details of the two meetings:|
|19th International SMA Researcher Meeting|
|June 18-20, 2015|
|Westin Crown Center, Kansas City, Missouri|
|BioBlast Presentation: Saturday June 20 @ 9:20am CDT|
|United Mitochondrial Disease Foundation - Mitochondrial Medicine 2015 Meeting|
|June 17-20, 2015|
|Hyatt Dulles, Herndon, Virginia|
|BioBlast Presentation: Friday June 19 @ 9:00am-10:30am EDT|
BioBlast Pharma is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. The company has a diverse portfolio of product candidates with the potential to address unmet medical needs for incurable genetic orphan diseases.
The BioBlast platforms are based on deep understanding of the disease-causing biological processes, and potentially offer solutions for several diseases that share the same biological pathology. For more information please visit the Company's website, www.bioblast-pharma.com, the content of which is not incorporated herein by reference.
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, we are using forward looking statements when we discuss our diverse portfolio of product candidates has the potential to address unmet medical needs for incurable genetic orphan diseases, or that our platforms potentially address unmet medical needs and offer solutions for several diseases that share the same biological pathology. In addition, historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials would not suggest different conclusions or that historic results would not be interpreted differently in light of additional research and clinical and preclinical trials results. Because such statements deal with future events and are based on BioBlast Pharma's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of BioBlast Pharma could differ materially from those described in or implied by the statements in this press release, including those discussed under the heading "Risk Factors" in BioBlast Pharma's Annual Report on Form 20-F filed with the Securities and Exchange Commission ("SEC") on March 31, 2015, and in any subsequent filings with the SEC. Except as otherwise required by law, BioBlast Pharma disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.
CONTACT: U.S. Investor Contact Andrew McDonald Founding Partner LifeSci Advisors, LLC Andrew@LifeSciAdvisors.com 646-597-6987Source: BioBlast Pharma